Evolution of the Average Target: Repligen Corporation

Evolution of the Target Price: Repligen Corporation

Changes in Analyst Recommendations: Repligen Corporation

4d1fa7b6339c2.zM_Dwl22L88jMEv0mTS-TQYkTU9dSEs_0xDuhXez9RM.gveGo27XH4taSgWTrkHKH3N9IjcwcHlPm1q95ifGkSufmI6hMeZB_0BXJA~5e39be2261dcaf30274b0ef2efab00ce
05-15 Repligen Likely to Benefit From Diverse Growth Factors, RBC Says MT
04-17 Rothschild & Co Redburn Initiates Repligen at Buy With $160 Price Target MT
02-25 UBS Adjusts Price Target on Repligen to $195 From $200, Maintains Buy Rating MT
01-16 UBS Adjusts Price Target on Repligen to $200 From $190, Maintains Buy Rating MT
25-10-01 HSBC Initiates Repligen at Buy With $150 Price Target MT
25-09-22 Repligen Shares Rise After Upgrade From Evercore ISI MT
25-09-22 Evercore ISI Upgrades Repligen to Outperform From In Line, Price Target is $155 MT
25-09-03 RBC Lifts Price Target on Repligen to $205 From $204, Keeps Outperform Rating MT
25-07-30 RBC Raises Price Target on Repligen to $204 From $193, Keeps Outperform Rating MT
25-07-29 Life sciences firm Repligen beats Q2 revenue estimates, raises full-year guidance RE
25-07-01 RBC Lifts Price Target on Repligen to $193 From $191, Keeps Outperform Rating MT
25-06-24 Barclays Initiates Repligen at Overweight With $150 Price Target MT
25-04-30 RBC Lowers Price Target on Repligen to $189 From $202, Keeps Outperform Rating MT
25-04-29 Wolfe Research Upgrades Repligen to Outperform From Peerperform MT
25-04-08 RBC Cuts Price Target on Repligen to $202 From $219, Keeps Outperform Rating MT
25-03-18 Evercore ISI Initiates Repligen at In Line With $155 Price Target MT
25-02-21 RBC Raises Price Target on Repligen to $205 From $203, Keeps Outperform Rating MT
25-02-21 Deutsche Bank Adjusts Repligen Price Target to $195 From $190, Maintains Buy Rating MT
25-02-10 TD Cowen Initiates Repligen at Buy With $200 Price Target MT
25-02-04 RBC Trims Price Target on Repligen to $203 From $207, Keeps Outperform Rating MT
24-12-09 RBC Lifts Price Target on Repligen to $207 From $205, Keeps Outperform Rating MT
24-11-14 Wolfe Research Initiates Repligen at Peer Perform MT
24-11-13 UBS Adjusts Price Target on Repligen to $190 From $185, Keeps Buy Rating MT
24-09-13 RBC Raises Price Target on Repligen to $205 From $190, Keeps Outperform Rating MT
24-07-31 UBS Lowers Repligen's Price Target to $185 From $205, Buy Rating Maintained MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+34.85%
+32.16%
+22.19%
+13.98%
+24.47%
+23.56%
+39.31%
+12.33%
+9.11%
+34.68%
Average +24.67%
Weighted average by Cap. +25.17%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
130.59USD
Average target price
176.11USD
Spread / Average Target
+34.85%
High Price Target
220.00USD
Spread / Highest target
+68.47%
Low Price Target
142.00USD
Spread / Lowest Target
+8.74%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Rothschild & Co Redburn
UBS
HSBC
Evercore ISI
RBC Capital Markets
Barclays
Wolfe Research
Deutsche Bank Securities
TD Cowen
Guggenheim
Benchmark Company
KeyBanc Capital Markets
Craig-Hallum
JPMorgan Chase
Stephens Inc.
Wells Fargo Securities
Stifel Nicolaus
SVB Securities LLC
SVB Leerink
Exane BNP Paribas
William O'Neil & Co
HC Wainwright
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
130.59USD
Average target price
176.11USD
Spread / Average Target
+34.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RGEN Stock
  4. Consensus Repligen Corporation
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!